Lyell Immunopharma develops engineered immune cell therapies for patients with cancer. It last closed at $13.80 on Nov 20, up 1.62% on the day. The next earnings report for LYEL is expected around Thu, Mar 11, 2027, after the close. For the quarter ended Sep 2026, LYEL reported EPS of -$1.86 on revenue of $3,000, with revenue down 80.0% from a year ago. Over its last 8 reports the stock moved an average of 4.1% the session after earnings. Over the last 12 months LYEL insiders bought $75.0M of stock on the open market and sold $613K, according to SEC Form 4 filings.
AI Auto Pilots
Is LYEL in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LYEL.
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha callBullish64%
OPTIONS
+2
DARK POOL
+1
HISTORY
0
TECHNICAL
+1
StreetAlpha's call on LYELStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in
LYEL · as of the Nov 20 close · updated each morning
Bounce inside a longer downtrend
The stock is 3% above its 20 day and 20% above its 50 day average. It is 17% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 55). The nearest support is the 20 day average at $13.41, and the nearest resistance the swing high (Jun 11) at $14.14.
Short trendBullish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityHigh, 9.2%/day
Key levels
$45.0052 week high+226.1%
$16.12200 day average+16.8%
$14.30Pivot R1+3.6%
$14.14Swing high (Jun 11)+2.5%
$13.80Pivot+0.0%
$13.80Last close
$13.4120 day average−2.8%
$13.39Swing low (Aug 17)−3.0%
$13.30Pivot S1−3.6%
$12.56100 day average−9.0%
$11.0850 day average−19.7%
$7.2052 week low−47.8%
Indicators
RSI (14)
55.44
Middle of its range
Neutral
MACD
0.98
Below its signal line
Bearish
Stochastic
45.3
Middle of its range
Neutral
ADX (14)
36.9
Trending up
Williams %R
-54.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
12.7
Oversold below −100, overbought above 100
Neutral
Rate of change
−7.1%
Change over 10 sessions
Bearish
ATR (14)
$1.27
Typical daily range, 9.2% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Below
Downtrend
Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityNormal, 18.9%/day
Key levels
$45.0052 week high+226.1%
$16.12200 day average+16.8%
$14.30Pivot R1+3.6%
$14.14Swing high (Jun 11)+2.5%
$13.80Pivot+0.0%
$13.80Last close
$13.4120 day average−2.8%
$13.39Swing low (Aug 17)−3.0%
$13.30Pivot S1−3.6%
$12.56100 day average−9.0%
$11.0850 day average−19.7%
$7.2052 week low−47.8%
Indicators
RSI (14)
50.65
Middle of its range
Neutral
MACD
-1.16
Above its signal line
Bullish
Stochastic
69.5
Middle of its range
Neutral
ADX (14)
17.7
No clear trend
Williams %R
-36.6
Oversold below −80, overbought above −20
Neutral
CCI (20)
45.7
Oversold below −100, overbought above 100
Neutral
Rate of change
+15.4%
Change over 10 sessions
Bullish
ATR (14)
$2.60
Typical daily range, 18.9% of price
MA 10Above
MA 20Above
MA 50Below
MA 100Below
MA 200Below
What happened before, for LYEL
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how LYEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
November seasonalityHow LYEL usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.
Whale options flow for LYELHow many large options trades hit LYEL, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in
No whale options trades in LYEL in the last 90 days.
From SEC Form 4 filings by LYEL's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper trading
StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LYEL is in one of them and how their past LYEL trades turned out.
Lyell Immunopharma is a clinical stage biotechnology company that develops cell therapies for patients with cancer. It takes immune cells from each patient and engineers them to better find and destroy cancer cells. Its lead candidate, rondecabtagene autoleucel, is being studied in patients with large B cell lymphoma, and the company is also developing LYL273 for advanced colorectal cancer. The company is based in South San Francisco, California.